ACTG 315 Preliminary Results: Drug Cocktail Restores Partial Immune Function

01/23/97 11: 27 0301 402 0395

N I H / f-, C /, D I

4
exciting horizons for understanding what happens in the course of disease itself in terms of
response to therapy."
Other related ACTG studies include ACTG 328, which is evaluating interleukin-2 plus
HAART directed at restoring the immune response, and ACTG 334, cyclosporin plus antiviral
therapies, aimed at blocking the immune activation that may potentiate viral replication.
NIAID, a component of the National Institutes of Health, conducts and supports research
aimed at preventing, diagnosing and treating illnesses such as AIDS and other sexually
transmitted disease, tuberculosis, asthma and allergies. NIIH is an agency of the U.S
Department of Health and Human Services.
NIAID press releases, fact sheets and other materials are available on the Internet via the
NIAID home page at http:/www.niaid.nih.gov.

The Nitional Insttitumeof Allcrgy mid Infirc-tivus 1DIseases
i'.a componen3C of the National I cStitutes of H k,
U.S. Department of Health and Human Scrvices

S7